• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on April 28, 2021August 2, 2023

Task Force Program Plays Key Role in COVID-19 Vaccine Safety Monitoring

Recent news of the possible complications of blood clots – or Thrombosis with Thrombocytopenia Syndrome (TTS) – following the...
Read More
Posted on March 24, 2021August 9, 2023

Benefit-Risk Working Group Call for Members

 The Benefit-Risk Assessment of Vaccines by TechnolOgy (BRAVATO) working group has developed standardized templates for the col...
Read More
Posted on February 22, 2021June 27, 2023

Press Release: CDC Taps The Task Force’s Expertise to Roll Out COVID-19 Vaccine in up to 50 Countries

The Centers for Disease Control and Prevention (CDC) has invested in The Task Force for Global Health (TFGH) to help low and mid...
Read More
Posted on December 30, 2020August 4, 2023

COVID-19 AESI List 2nd Quarterly Update (December 2020)

SPEAC has completed a second update of the COVID-19 clinical literature covering the period of August 8 through November 13th 202...
Read More
Posted on December 12, 2020June 27, 2023

Ensuring Safety of COVID-19 Vaccines: Q&A with Robert Chen

Robert Chen, the Scientific Director of Brighton Collaboration, discussed the safety profiles of COVID-19 vaccines with the Coali...
Read More
Posted on September 30, 2020September 22, 2023

Brighton Collaboration Added to Vaccine Safety Net

Brighton Collaboration (BC) has been added to the Vaccine Safety Net (VSN). VSN is a global network of websites, established by t...
Read More
Posted on August 18, 2020June 27, 2023

New Working Groups to be Established to Develop Guidance on Digital Apps for Vaccine Safety Data Collection

Digital apps have much potential for improving the quality of safety data collected during both pre and post-introduction of new...
Read More
Posted on June 12, 2020June 27, 2023

New Brighton Collaboration Working Groups to be Established to Develop Case Definitions for Four COVID-19 Adverse Events of Special Interest (AESI)

The Coalition for Epidemic Preparedness Innovation (CEPI) has partnered with the Brighton Collaboration to support the safety asse...
Read More
Posted on January 2, 2020June 27, 2023

Sign up for Brighton Collaboration 2.0 Membership!

Our previous post entitled Transition of Brighton Collaboration informed you of several new developments to strengthen the Brigh...
Read More
Posted on May 28, 2019August 9, 2023

CEPI partners with Brighton Collaboration to support safety assessment of vaccine candidates

The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration, based in Atlanta at The Task Force fo...
Read More
Previous page 1 2 3 4 5 Next page

Recent Posts

  • Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa feverJune 2, 2025
  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy